Many general anesthetics with simple chemical structures prolong the duration of synaptic inhibition via allosteric regulation of GABA A receptors Nishikawa and MacIver, 2000) . Reciprocal synaptic connections between cortical interneurons can generate high-frequency (30 -60 Hz) oscillatory activity , and entrainment of these local inhibitory microcircuits results in synchronization of these "gamma oscillations" (Whittington et al., 1995) . Such high-frequency activity has been linked to cognitive functions such as selective attention (Bragin et al., 1995) , and these oscillations are highly sensitive to disruption by central depressants (Faulkner et al., 1998) . GABAergic inhibition plays a fundamental role in the timing of these high-frequency oscillations, so that drugs that prolong the time course of synaptic inhibition also decrease the characteristic frequency of these oscillations , eventually imposing slow, highamplitude waves in both the EEG and in vitro model systems. Decreases in the EEG spectral edge frequency accompany decrements in cognitive function during the induction of anesthesia (Rampil, 1998) . GABA A receptors therefore represent one of the major neurobiological substrates for the action of general anesthetics, especially with regard to the ability of these drugs to induce hypnosis and loss of consciousness (Franks and Lieb, 1994) .
Inhaled anesthetics alter the function of GABA A receptors in acutely dissociated neurons (Nakahiro et al., 1989; Wakamori et al., 1991; Li and Pearce, 2000) and in heterologous expression systems Mihic et al., 1997; Jenkins et al., 1999) . The modulatory action of these inhaled agents, unlike that of diazepam, is independent of the ␥ subunit of the GABA A receptor Krasowski et al., 1998; Koltchine et al., 1999) . In this study, we have therefore examined the action of these anesthetics on GABA A receptors consisting only of ␣ and ␤ subunits. GABA A receptor modulation by the anesthetic ether isoflurane is abolished by a point mutation at S270 in the TM2 segment of the ␣ subunit (Mihic et al., 1997; Krasowski et al., 1998) , whereas the effects of diazepam and other sedative-hypnotic benzodiazepines are abolished by mutating H101 to arginine in the large extracellular N-terminal domain of the ␣ subunit (Rudolph et al., 1999; McKernan et al., 2000) . However, although it is known that flunitrazepam binds to H101 but not R101 (Duncalfe et al., 1996) , it is not known why S270 permits receptor modulation by isoflurane, whereas an isoleucine residue at this position does not. The present study probes the involvement of S270 and of two other residues in greater detail and extends our analysis of anesthetic action to include the alkanes halothane and chloroform.
MATERIALS AND METHODS
Site-directed mutagenesis and electrophysiolog y. To create the mutant series at GABA A receptor ␣2 Ser270, mutations were introduced into the cDNA encoding the human GABA A receptor ␣2 subunit at bases 890 to 892, with simultaneous loss of a DdeI restriction site (Koltchine et al., 1999) . Additional mutations were created at Ala291 and Leu232 using either the Unique Site Elimination method (Amersham Pharmacia Biotech, Arlington Heights, IL) or a Pfu polymerase/DpnI selection method (QuikChange; Stratagene, La Jolla, CA). The sequences of all cDNA inserts were confirmed throughout by double-stranded sequencing. Human embryonic kidney (H EK) 293 cells were maintained in culture on glass coverslips and transfected with cDNAs encoding wild-type or mutant ␣2 subunits and wild-type ␤1 subunits. Recordings were made using the whole-cell patch-clamp technique as described previously (Koltchine et al., 1999) . All drugs and solutions were applied rapidly to the cell by local perf usion using a motor-driven solution exchange device; recordings were made at room temperature (20 -22°C). Bath concentrations of the anesthetics were measured using gas chromatography and represent 90 -95% of the total applied drug concentration. Numerical data are presented throughout as mean Ϯ SE. Concentrationresponse curves were determined for the wild-type and each mutant GABA A receptor (Koltchine et al., 1999) . Potentiation of a submaximal GABA response by each anesthetic was then calculated as the percentage increase above the control (EC 20 ) response to GABA in the presence of anesthetic (Koltchine et al., 1999) .
Molecular volume calculation. Molecules were built in Spartan V5.1 (Wavef unction, San Diego, CA) and optimized with the Merck MM FF94 forcefield. The calculated volumes are van der Waals volumes and are given in Å 3 .
RESULTS

Different mutations are required to remove sensitivity to different anesthetics
The wild-type ␣2␤1 GABA A receptor is potentiated by isoflurane and halothane (Fig. 1a) . The mutant receptor ␣2(S270H)␤1 is insensitive to isoflurane (Krasowski et al., 1998) but shows normal sensitivity to the alkane anesthetic halothane (Fig. 1b) . This finding initially suggested to us that S270 in TM2 might participate in binding isoflurane, but not halothane. The TM1 segment of the homologous glycine receptor was recently inferred to confer sensitivity to halothane (Greenblatt and Meng, 1999) ; we subsequently observed that the mutant GABA A receptor ␣2(L232F)␤1 was insensitive to halothane, whereas sensitivity to isoflurane remained (Fig. 1c) . This finding suggested initially that L232 in TM1 might participate in binding halothane, but not isoflurane, and pointed to the possibility that these two anesthetics might act at different sites on the GABA A receptor. However, when a larger Trp residue was introduced at S270, the mutant receptor ␣2(S270W)␤1 was shown to lack sensitivity to halothane, as well as isoflurane (Fig. 1d) . Interestingly, this receptor retained sensitivity to a third anesthetic, chloroform (Fig. 1e ). Mutation at A291 in TM3 of the ␣ subunit has previously been shown to abolish receptor regulation by isoflurane (Krasowski et al., 1998) , and we therefore added a second Trp residue at this position to create the double mutant ␣2(S270W; A291W)␤1 receptor. This receptor was completely insensitive to chloroform (Fig. 1e) , isoflurane, and halothane, but retained sensitivity to propofol (data not shown), an anesthetic believed to exert its actions via a site on the ␤ subunit (Sanna et al., 1995; Krasowski et al., 1998) . The idea that the three residues (L232, S270, and A291) could be mutated to selectively or completely remove anesthetic modulation was then tested further. The S270W mutation was sufficient to remove isoflurane and halothane sensitivity, whereas the L232F mutation was sufficient to block potentiation by halothane but not isoflurane; in light of these observations, we also mutated L232 to tryptophan. The ␣2(L232W)␤1 receptor expressed at normal levels and, like the ␣2(S270W)␤1 receptor, was insensitive to potentiation by both halothane (Ϫ1.5 Ϯ 4.8%; n ϭ 20 cells) and isoflurane (5.8 Ϯ 4.6%; n ϭ 20 cells).
Anesthetics of dissimilar size have different cutoffs
The isoflurane sensitivity of the GABA A receptor appears to show a cutoff effect when the receptor is mutated to increase the size of the residue at ␣270 (Koltchine et al., 1999) . Specifically, in the series of mutant receptors ␣2(S270X)␤1, these receptors become insensitive to isoflurane (molecular volume 144 Å 3 ; Fig.  2a ), because the volume of the side-chain is increased beyond the volume of threonine, i.e., after a change in volume ␦V Ͼ 30 Å 3 (Fig. 2a) . We repeated this analysis with the physically smaller anesthetics halothane (molecular volume 110 Å 3 ) and chloroform (molecular volume 90 Å 3 ), and in each case, a cutoff phenomenon was again observed. However, the cutoff occurred at larger side chain volumes than for isoflurane. For halothane this occurs between ␦V ϭ 100 -140 Å 3 (Fig. 2b) , whereas for chloroform the cutoff occurs between ␦V ϭ 240 -280 Å 3 (Fig. 2c) .
DISCUSSION
Multiple cutoffs suggest a common interaction site for three general anesthetics
We explain these experimental data by proposing that the sidechains at the key positions L232, S270, and A291 (in transmem- Figure 1 . Effects of three general anesthetics on wild-type and mutant GABA A receptors. All receptors were expressed in HEK 293 cells and studied using whole-cell voltage-clamp recording at Ϫ60 mV (Krasowski et al., 1998) . Currents were activated by EC 20 concentrations of GABA. a, Isoflurane and halothane enhance responses to GABA in wild-type ␣2␤1 GABA A receptors. b, In mutant ␣2(S270H)␤1 receptors, the enhancing effect of isoflurane is absent, whereas the halothane effect is preserved. c, In mutant ␣2(L232F)␤1 receptors, the enhancing effect of halothane is absent, whereas the isoflurane effect is preserved. d, In mutant ␣2(S270W)␤1 receptors, neither halothane nor isoflurane enhances GABA responses. e, Effects of chloroform on wild-type and mutant GABA A receptors. Chloroform potentiated the actions of GABA in wildtype ␣2␤1 GABA A receptors, and this effect was preserved in mutant ␣2(S270W)␤1 receptors but abolished in the double mutant ␣2(S270W; A291W)␤1 receptor. The anesthetic concentrations used in the figures were as follows: isoflurane, 0.5 mM; halothane, 0.32 mM; and chloroform, 0.9 mM. Calibration: 50 pA (vertical axis), 10 sec (horizontal axis).
brane segments TM1, TM2, and TM3, respectively, of the ␣ subunit) define a binding cavity for small anesthetic molecules. Given our knowledge of the molecular volumes of the anesthetics and the cutoff data from our experiments, the volume of this hypothetical cavity can be estimated as between 250 and 370 Å 3 . The introduction by mutagenesis of bulky side chains at the critical sites presumably decreases the molecular volume of the anesthetics that can be accommodated within such a cavity. It should be noted that these cutoff effects are independent of anesthetic concentration (Koltchine et al., 1999) .
The present results highlight the importance of the TM domains for receptor activation and regulation; mutating selected residues in the TM1 (Thompson et al., 1999) , TM2 (Koltchine et al., 1999) , and TM3 (Krasowski and Harrison, 2000) domains often results in changes in GABA EC 50 . These mutations also affect the sensitivity of the receptor to a variety of allosteric modulators. For example, in addition to the changes in anesthetic sensitivity reported here, a mutation in TM1 ␣1(T230I) renders ␣1*␤3␥2s receptors more sensitive to the ␣6-specific noncompetitive antagonist furosemide; a similar result can be achieved by mutating (N265) in the ␤3 subunit (Thompson et al., 1999) .
Three additional features of the experimental data are noteworthy. First, the data for the L232F and S270H mutants suggest that the anesthetics do not fit into the putative binding cavity in an identical manner; isoflurane (unlike halothane) is active at the L232F mutant receptor, whereas halothane (unlike isoflurane) is active at the S270H mutant. This could be explained if halothane makes a closer contact with L232 than does isoflurane, which may instead lie closer to S270, accounting for the very sharp cutoff in Figure 2a . The loss of sensitivity to both isoflurane and halothane after additional volume is added in the L232W or S270W mutants supports this idea and suggests that these two residues are part of the same cavity. Second, whereas the ability of isoflurane to enhance GABA currents falls off drastically as side-chain volume is increased at the 270 position, from serine to phenylalanine, halothane actually increases in effectiveness as the residue at 270 is expanded, before reaching the cutoff point at tryptophan. It is possible that for halothane (unlike isoflurane), the binding interactions with TM2 may be suboptimal in the wild-type receptor and are actually improved by the addition of a bulky side chain at 270. Finally, there is a marked discontinuity in the data for chloroform, at ϳѨV ϭ 40 Å 3 . One explanation for this observation would be a change from a cavity occupied by two chloroform molecules in the Asn mutant to a singly occupied cavity in the Glu mutant. If a cavity of Ͼ250 Å 3 does exist within the wild-type ␣ subunit, it should be possible for two molecules of chloroform (90 Å 3 ) to bind simultaneously within such a cavity. There are existing precedents for double occupancy of cavities by general anesthetic molecules; for example, two molecules of halothane arranged in a head-tohead orientation are found within one of the anesthetic binding sites in human serum albumin (HSA) (Bhattacharya et al., 2000) .
Small cavities bind general anesthetic molecules
Small cavities have been demonstrated to exist in a variety of globular proteins, both natural (Tilton et al., 1984; Eriksson et al., 1992; Kono et al., 2000) and synthetic (Johansson et al., 2000) in origin, and these can be altered in size and shape by mutagenesis of appropriate residues (Eriksson et al., 1992; Brunori et al., 2000; Kono et al., 2000; Lee et al., 2000) . Anesthetics and other small gas molecules have been demonstrated to occupy such cavities, using a variety of techniques (Tilton et al., 1984; Franks et al., 1998; Brunori et al., 2000; Johansson et al., 2000) . The binding of the anesthetic bromoform within a cavity in the enzyme firefly luciferase has been demonstrated using x-ray crystallography (Franks et al., 1998) . Binding of such small ligands to protein cavities is often accompanied by the displacement of bound water molecules (Rashin et al., 1986; Matthews et al., 1995) , and the interactions are further stabilized by low-energy (Յ2-4 kcal/mol) van der Waals interactions with the cavity surface. The resulting free energy changes, although small, are commensurate with the relatively small energy changes associated with the gating of ligand-gated ion channels and are consistent with the low potencies for the anesthetic agents studied here (10 Ϫ 4 -10 Ϫ 3 M). More recently, Bhattacharya et al. (2000) have obtained the highresolution (2.4 Å) structure of halothane bound to HSA. In all of these cases, anesthetic binding produced no change in local or global protein structure. Instead, the halothane molecules simply occupied pre-existing cavities and made contacts with small polar and apolar amino acids forming the cavity walls.
An anesthetic binding cavity of defined volume in the GABA A receptor
The existence of a similar cavity or "crevice" within the GABA A receptor is supported by data from scanning cysteine accessibility mutagenesis experiments on TM3 in the ␣ subunit (Williams and Figure 2 . The effect of the addition of molecular volume by mutagenesis at positions 270 or 291 on GABA A receptor regulation by three anesthetics. Above the figure are representations of the molecular volumes of the three anesthetics. a, Addition of molecular volume produces a cutoff for isoflurane at ѨV ϭ 30 -40 Å 3 . b, A cutoff is observed for halothane at ѨV ϭ 140 Å 3 . c, A cutoff for chloroform is not observed until ѨV ϭ 280 Å 3 . The data for each anesthetic at each mutant receptor are expressed as the mean Ϯ SEM of the percentage enhancement (potentiation) of the current response to an EC 20 concentration of GABA appropriate to that receptor, plotted against ѨV, the increase in molecular volume produced by mutagenesis.
